Home » Stocks » TENX

Tenax Therapeutics, Inc. (TENX)

Stock Price: $1.86 USD -0.02 (-1.06%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
Market Cap 46.87M
Revenue (ttm) n/a
Net Income (ttm) -30.94M
Shares Out 14.52M
EPS (ttm) -3.33
PE Ratio n/a
Forward PE 13.72
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $1.86
Previous Close $1.88
Change ($) -0.02
Change (%) -1.06%
Day's Open 1.86
Day's Range 1.86 - 1.88
Day's Volume 19,672
52-Week Range 0.80 - 3.68

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

New York, New York--(Newsfile Corp. - July 16, 2021) - Levi & Korsinsky announces it has commenced an investigation of Tenax Therapeutics, Inc (NASDAQ: TENX) concerning possible breaches of fiduciary du...

1 week ago - Newsfile Corp

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) announces retirement of CEO Anthony A. DiTonno, Christopher T. Giordano as new CEO and $10 million PIPE.

2 weeks ago - Business Wire

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) announces inclusion in the Russell Microcap® Index after the U.S. market opens on June 28, 2021

1 month ago - Business Wire

New York, New York--(Newsfile Corp. - June 7, 2021) -  Levi & Korsinsky announces it has commenced an investigation of Tenax Therapeutics, Inc (NASDAQ: TENX) concerning possible breaches of fiduciary du...

1 month ago - Newsfile Corp

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) announces first quarter 2021 financial results and provides business update.

2 months ago - Business Wire

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax announced the publication of positive data from the company's Phase 2 HELP Study in the Journal of American College of Cardiology: Heart Failure

3 months ago - Business Wire

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax announced that Ronald R. Blanck, D.O., Gregory Pepin and Chris A. Rallis have voluntarily agreed to step down from the Board of Directors.

3 months ago - Business Wire

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) today reported financial results for the year ended December 31, 2020 and provided a business update

3 months ago - Business Wire

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (NASDAQ: TENX) to present company overview at H.C. Wainwright Global Life Sciences Virtual Conference held March 9-10, 2021

4 months ago - Business Wire

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (NASDAQ: TENX) appoints June Almenoff, MD, PhD, Michael Davidson, MD, Delcan Doogan, MD, and Stuart Rich, MD to its Board.

4 months ago - Business Wire

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) to host conf. call & live audio webcast on Jan 21, 2021, at 4:30 pm to discuss acquisition of PH Precision Med

6 months ago - Business Wire

A slew of biopharma stocks are making big moves Tuesday on the back of clinical trial readouts as well announcements regarding M&A and tie-ups. Merus, Lilly In $1.68B Oncology Deal: Dutch-based Merus NV...

Other stocks mentioned: ACRS, CYAD, GRTS, MRUS, NERV
6 months ago - Benzinga

Tenax Therapeutics (TENX) stock is flying high on Tuesday after announcing it has acquired biotech company PH Precision Med. The post TENX Stock: 8 Things to Know About Tenax Therapeutics and PH Precisi...

6 months ago - InvestorPlace

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (NASDAQ: TENX) acquires PH Precision Med (PHPM), adding imatinib to its pipeline. Stuart Rich, MD joins as CMO.

6 months ago - Business Wire

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) today reported financial results for the third quarter 2020 and provided a business update

8 months ago - Business Wire

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) announces HELP Study presented at American Heart Association (AHA) Scientific Sessions available Nov. 13th

8 months ago - Business Wire

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (NASDAQ: TENX) will host a virtual R&D webinar for analysts and investors on Wednesday, November 18, 2020 at 4:30 p.m. EST

8 months ago - Business Wire

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (NASDAQ: TENX) announces amendment to Orion License Agreement adding oral levosimendan.

9 months ago - Business Wire

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (NASDAQ: TENX) announces presentation of Phase 2 HELP Study at virtual meeting of HFSA on Saturday, Oct 3, 2020 @ 4:30 pm EDT

9 months ago - Business Wire

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc.

10 months ago - Business Wire

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc.

10 months ago - Business Wire

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc.

11 months ago - Business Wire

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc.

1 year ago - Business Wire

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) Announces $8MM Registered Direct and PIPE Offering with single healthcare-focused institutional investor

1 year ago - Business Wire

Shares of nano-cap Tenax Therapeutics Inc (NASDAQ: TENX), are advancing strongly Tuesday in the wake of a positive clinical readout.

1 year ago - Benzinga

About TENX

Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. The company develops levosimendan, which completed a phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction; and Imatinib, a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeu... [Read more...]

Industry
Biotechnology
Founded
1967
CEO
John Kelley
Employees
9
Stock Exchange
NASDAQ
Ticker Symbol
TENX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for TENX stock is "Buy." The 12-month stock price forecast is 4.75, which is an increase of 155.38% from the latest price.

Price Target
$4.75
(155.38% upside)
Analyst Consensus: Buy